Neurocrine Biosciences Inc. (NBIX) bad news but its only down a little after hours i wonder why? anyone have any ideas Results of statistical analysis using the intent-to-treat population revealed no benefit of GSK561679 compared with placebo on both the Bech Melancholia and HAMD-17 endpoints. The top-line results are based on the six week placebo-controlled portion of the study for the intent to treat population of 145 patients. From a safety perspective, there were no significant adverse events, and the drug was generally well tolerated. i wonder why? anyone have any ideas
i guess we have to wait until wednesday...either the news is not important or after hours is a bunch of bull either way i wont get much sleep
for that bad of news...NBIX could not be having a better day well its either a super strong stock that can shrug off bad news...which are the stocks that can change your life style or that drug trial was a long shot to be good and everyone knew it... i dont know????
well i guess this is why it was up last week 8:01AM Neurocrine Biosci announces that VMAT2 program will move into Phase II clinical trials (NBIX) 8.04 : Co announces that it has successfully completed a second Phase I clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The positive results of this Phase I study of repeated dosing in healthy volunteers allows the VMAT2 program to initiate Phase II studies.
Neurocrine Biosciences Inc. (NBIX)- I have been waiting for big news Good or Bad for a long time now....something big has to come out sooonnn At this point i just want big news..... Anyone know of anytime frames for these drug trials to be complete??